Factors Associated With Hospital and Intensive Care Admission in Paediatric SARS-CoV-2 Infection: A Prospective Nationwide Observational Cohort Study

Anita Uka
University of Fribourg Faculty of Science and Medicine: Universite de Fribourg Faculte de sciences et de medecine  https://orcid.org/0000-0003-4793-660X

Michael Buettcher
Cantonal Hospital Lucerne Children's Hospital: Luzerner Kantonsspital Kinderspital Luzern

Sara Bernhard-Stinemann
Cantonal Hospital Aarau: Kantonsspital Aarau AG

Yves Fougère
Lausanne University Hospital: Centre Hospitalier Universitaire Vaudois

Dehlia Moussaoui
Geneva University Hospitals: Hopitaux Universitaires Geneve

Lisa Kottanattu
Repubblica e Cantone Ticino Ente Ospedaliero Cantonale

Noémie Wagner
Geneva University Hospitals: Hopitaux Universitaires Geneve

Petra Zimmemann
University of Fribourg Faculty of Science: Universite de Fribourg Faculte de sciences et de medecine

Nicole Ritz ( Nicole.ritz@unibas.ch )
University Children's Hospital Basel: Universitats Kinderspital beider Basel

Swiss Paediatric Surveillance Unit (SPSU)
Federal Office of Public Health: Bundesamt fur Gesundheit

Research Article

Keywords: COVID-19, child, epidemiology, clinical presentation, outcome, transmission

DOI: https://doi.org/10.21203/rs.3.rs-517119/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Coronavirus disease 2019 (COVID-19) is usually less severe in children compared to adults. This study describes detailed clinical characteristics, treatment and outcomes of children with laboratory-confirmed COVID-19 in a non-hospitalised and hospitalised setting and quantifies factors associated with admission to hospital and intensive care unit in children with SARS-CoV-2 infection on a nationwide level.

Data were collected through the Swiss Paediatric Surveillance Unit from children < 18 years with laboratory-confirmed SARS-CoV-2 infection. All 33 paediatric hospitals in Switzerland reported non-hospitalised and hospitalised cases from March 1 to October 31, 2020 during both pandemic peaks.

In total, 678 children were included. The median age was 12.2 (IQR 5.0 – 14.6) years, 316 (47%) were female and 106 (16%) had comorbidities. Overall, 126 (18.6%) children were hospitalised of whom 16 (12.7%) required ICU admission. Comorbidities were the only factor associated with hospital admission in a multivariable regression analysis (odds ratio 3.23, 95%CI 1.89 to 5.50; p-value <0.01). Hospitalised children more often presented with fever (96 [76.2%] vs 209 [38.1%], p-value<0.01) and rash (16 [12.8%] vs 6 [1.1%], p-value<0.01). Anosmia/dysgeusia was more prevalent in non-hospitalised children (73 [13.3%] vs 3 [2.4%), p-value<0.01). In the hospitalised children, oxygen treatment was required in 34 (27.0%), inotropes in nine (7.3%) and mechanical ventilation in eight (6.3%). Complications were reported in 28 (4.1%) children with cardiovascular complications being most frequent (11 [1.6%]). Three deaths were recorded.

Conclusion: This study confirms that COVID-19 is mostly a mild disease in children. Fever, rash, and comorbidities are associated with higher admission rates. Continuous observation is necessary to further understand paediatric COVID-19, guide therapy and evaluate the necessity for vaccination in children.

What Is Known

- Clinical manifestations of SARS-CoV-2 infection in children vary from asymptomatic to critical disease requiring ICU admission.
- Most studies are based on hospitalised children only, currently there is limited data on non-hospitalised children.

What Is New

- This is a large national multicentre study provides detailed clinical data on non-hospitalised and hospitalised children with laboratory-confirmed SARS-CoV-2 infection.
- The clinical spectrum and severity of COVID-19 is influenced by age. In children less than 2 years, fever, cough, and rhinorrhea are the most common symptoms and in adolescents fever, cough and headache are more common.
Hospitalised children more often presented with fever and rash, while anosmia/dysgeusia is more prevalent in non-hospitalised children.

Children with pre-existing comorbidities are more frequently admitted to hospital but do not require ICU admission more often.

Introduction

Compared to adults, the new coronavirus disease 2019 (COVID-19) manifests differently in infants, children and adolescents.\textsuperscript{1–5} Although, the disease severity is often milder in children, paediatric patients may also develop severe disease requiring admission to intensive care unit (ICU) and may very rarely die from COVID-19.\textsuperscript{6–8} Additionally, children presenting with a delayed inflammatory disease called ‘paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2 (PIMS-TS)’ or ‘multisystem inflammatory syndrome in children (MIS-C)’ have been reported.\textsuperscript{7,9–15}

To date, the data on SARS-CoV-2 infection in children and adolescents either come from non-admitted children with limited clinical information or from hospitalised children only. This limits the knowledge in paediatric COVID-19 on factors associated with admission including clinical presentation and risk factors such as age, sex, or comorbidities. This nationwide study presents the first epidemiological data from active surveillance of SARS-CoV-2 infections in non-hospitalised and hospitalised children in Switzerland.

Method

Study design and population

Paediatric SARS-CoV-2 infections are actively monitored in an observational study by the Swiss Paediatric Surveillance Unit (SPSU, \url{http://www.spsu.ch}) since March 2020. The current analysis includes data from March 1 to October 31, 2020. All 33 paediatric and neonatological hospitals in Switzerland participated and notify cases monthly. Upon notification the investigators sent the reporting centres an electronic clinical report form through RedCap or in paper form (see supplementary data Questionnaire).\textsuperscript{16} Epidemiological, clinical and therapeutical data were recorded anonymously. All data were reviewed by the investigators and further clarified with the reporting physician when needed. The study has received ethical approval by the Ethikkommission Nordwest- und Zentralschweiz (EKNZ 2020-01130).

Case definition

Children and adolescents < 18 years of age who presented to a Swiss paediatric hospital and received ambulatory or hospitalised care were included if diagnosed with COVID-19 either by the detection of SARS-CoV-2 from a clinical specimen using a validated polymerase chain reaction (PCR) or serology. Retrospective screening of patients with the following criteria was used for identification of potential
PIMS-TS cases: PIMS-TS reported by the clinician as complication, SARS-CoV-2 serology performed, ICU admission or cardiac changes.

**Statistical analysis**

Continuous data were summarised using median and interquartile ranges. Categorical data were presented as percentage. Categorical data were compared using the $c^2$ test, with p-values <0.05 considered as significant. Co-occurrence symptoms were clustered using the K-means clustering solution and visualised with a heat map. A multivariable logistic regression model of risk of admission was fitted by including all variables used for univariable analysis origin. For the assessment of age, the following groups were made 0 to <2, 2 to <5, 5 to <10 and 10 to <18 years of age. R (Version 1.2.5019) was used for statistical analyses.

**Results**

**Study population**

A detailed dataset was returned for 682 cases, of which 678 were included in the final analysis. Reasons for exclusion were duplication in reporting (n=3) and age ≥ 18 years (n=1). The age of the children ranged from 7 days to 17.9 years with a median of 12.2 years (interquartile range (IQR) 5.0 – 14.6) (Table 1). Most of the children were Caucasian (532 [78.5%]), followed by Arabic (29 [4.3%]), Hispanic (27 [4.0%]), Black (18 [2.7%]) and Asian (10 [1.5%]). Ethnicity was unknown for 62 (9.1%) children. Numbers of reported children over time are shown in Figure 1 and stratified to age group in supplementary data Figure S1. Geographical and temporal distribution of SARS-CoV-2 cases in Swiss cantons (political states) are shown in supplementary data Figure S2.

**Hospitalisation and management**

Overall, 126 (19%) children were hospitalised of which 14 (11.1%) were admitted for other reasons than infection with SARS-CoV-2. A total of 16 (12.7%) children required ICU admission for the following reasons: hemodynamic instability (n=8), respiratory failure (n=4), prematurity (n=1), coma (n=1), cardiovascular arrest (n=1), neurogenic shock (n=1). One adolescent with a mild upper respiratory tract illness was admitted to ICU for a non-COVID-19-related reason (neurogenic shock after an accident). Ethnicity of the children admitted to ICU were Caucasian (n=8), Black (n=4), Hispanic (n=3), and unknown (n=1). Oxygen was required in 34 (27.0%), inotropes in nine (7.3%) and mechanical ventilation in eight (6.3%) hospitalised cases. Complications were reported in 28 (22.2%) hospitalised children with cardiovascular complications being most frequent (10 [7.9%]). A total of 48 children were retrospectively analysed for potential PIMS-TS of which 17 children were identified as cases based on available data (eight non-ICU admitted, nine ICU admitted). Three deaths were recorded.
Overall, most children (646 [95.3%]) did not receive medication. Specific treatment was given to 10 (1.8%) of non-hospitalised, 15 (13.6%) of hospitalised and 12 (75.0%) of ICU-admitted children. Among hospitalised children (non-ICU admitted), six (5.5%) received corticosteroids, two (1.8%) each hydroxychloroquine and intravenous immunoglobulins and one (0.9%) tocilizumab. Among ICU-admitted children nine (56.3%) received biologicals (anakinra [n=7], tocilizumab [n=2]), seven (43.8%) each corticosteroids, intravenous immunoglobulins and two (12.5%) hydroxychloroquine. No further treatment including remdesivir was given (supplementary data Questionnaire). The median duration of hospitalisation for non-ICU admitted children was 3.0 (IQR 2.0 - 4.0) days and for children admitted to ICU 14 (IQR 4.75 – 15.25) days (supplementary data Figure S3).

**Comorbidities**

A total of 106 (15.6%) children had pre-existing medical conditions, the most common comorbidities were reported in the following groups: respiratory (45 [42.5%]), endocrinology (15 [14.2%]), haemato-oncology (12 [11.3%]) and cardiovascular (10 [9.4%]) (details are listed in Table 2). Hospitalised children had significantly more comorbidities than non-hospitalised children (p-value < 0.01). Five (31.3%) children admitted to ICU had pre-existing comorbidities: three children had asthma/bronchitis, a neonate had apnoea of prematurity (born at 29 weeks gestational age) and a 2-month-old infant had isolated microcephaly with a normal cerebral ultrasound and no evidence of Cytomegalovirus in urine. Children requiring admission to ICU did not have more frequently pre-existing medical conditions compared to non-ICU hospitalised children. The univariable regression analysis showed that children ≥ 2 years of age were less likely to be hospitalised and comorbidities increased the risk of hospitalisation in both the uni- and the multivariable analysis (Table 3).

**Symptoms**

Overall, fever was the most frequent symptom observed among children with COVID-19 (305 [45.3%]) (Table 1). In children aged less than 2 years, fever, cough, and rhinorrhea were the most common symptoms and in adolescents between 10 and 18 years of age, fever, cough and headache were more commonly reported (a detailed distribution of symptoms according to age group is presented in Figure 2). Fever and rash were more common in hospitalised compared with non-hospitalised children ((96 [76.2%] vs 209 [38.1%], p-value <0.001) and (16 [12.8%] vs 6 [1.1%], p-value <0.001), respectively. In contrast, anosmia/dysgeusia was more prevalent in non-hospitalised children (73 [13.3%] vs 3 [2.4%], p-value 0.001). Children admitted to ICU more often had abdominal pain (5 [33.3%] vs 11 [10.0%, p-value 0.034) and rash (5 [33.3%] vs 11 [10.0%, p-value 0.034) than non-ICU hospitalised children. A heatmap with a co-occurrence matrix for symptoms showed three clusters of symptoms representing three different clinical phenotypes (Figure 3). The first cluster represents an upper respiratory tract illness with fever, cough, rhinorrhea, and pharyngitis, the second a gastrointestinal illness with abdominal pain, diarrhoea and vomiting, and the third cluster corresponds to more constitutional symptoms with headache, myalgia and asthenia.
Complications

A total of 28 (4.1%) children with SARS-CoV-2 infection developed complications, this was more frequent in hospitalised than non-hospitalised children (p-value <0.001). The most frequent complications/non-pulmonary organ manifestations were cardiovascular in 11 (1.6%) children, including coronary artery dilatation (n=4), elevation of cardiac enzymes (n=3), hypotensive shock (n=3), myocarditis (n=1), vasculitis (n=3). Bacterial co-infection was reported in 10 (1.5%) children, exclusively in hospitalised children. Further complications were: pancytopenia (n=5), kidney failure (n=4), seizures (n=3), encephalopathy (n=1), polyradiculoneuritis (n=1) and myopathy (n=1).

In hospitalised cases three (2.4%) deaths were reported during the study period. A 10-month-old infant with severe brain oedema, signs of hypoxic-ischemic encephalopathy and cerebral haemorrhages presenting with vomiting without fever, respiratory distress (with evidence of respiratory illness on chest radiography) and status epilepticus. A 2-month-old infant with cardiorespiratory arrest secondary to cerebral haemorrhage presenting with pale stools, haematochezia, haematemesis and hepatosplenomegaly with abnormal liver function. A 6-year-old with an Epstein-Barr Virus (EBV)-associated hemophagocytic lymphohistiocytosis developed cerebral bleeding due to coagulation deficiency caused by liver failure. He presented with abdominal pain, fever and abnormal liver function two weeks after a SARS-CoV-2 infection and was initially suspected to have PIMS-TS.

Diagnosis

Diagnosis was mostly confirmed by a single nasopharyngeal PCR (620 [96.3%]). Of the 40 children in whom serology was done, 35 (87.5%) were positive. Five (55.6%) ICU-admitted patients had positive serology with negative PCR. A chest radiography was done in 47 (6.9%) children and showed unilateral and bilateral changes in six (12.8%) and 16 (34.0%) cases, respectively. Echocardiography was done in 47 (6.9%) children, abnormal findings were identified in eight (21.6%) children (coronary dilatation (n=4), reduced left ventricle ejection fraction (n=3), dyskinesia (n=1)), all of them were hospitalised. Other diagnostic tests included abdominal ultrasound (21 [3.1%]) and thoracic CT-scan (10 [1.5%]) (further details in supplementary data Table S1).

Transmission

In total, 309 children (45.6%) had a family member with a confirmed or suspected SARS-CoV-2 infection (supplementary data Figure S4). Community-acquired infection (including school and day-care) was confirmed or suspected in 86 (12.7%) children. In one third of children, the primary case was unknown 284 (41.9%).

Discussion

Our study is a prospective nationwide observational cohort study that describes detailed clinical characteristics and outcomes of children with laboratory confirmed COVID-19 in a non-hospitalised and
Our findings suggest that comorbidities were an important factor with two times higher hospitalisation rates in children and adolescents with reported comorbidities. Data from the COVID-19 Centres of Disease Control surveillance of in the United States, suggest that overall hospitalisation rates were six times higher among patients with a reported underlying condition than those without reported underlying condition.\textsuperscript{17} In the paediatric age group (≤ 9 years of age) the rate of underlying conditions was reported to be 4.1% in all children and 22.3% in those admitted. We have found similar rates of comorbidities in admitted children but higher ones in non-hospitalised patients. The latter is likely explained by the fact that our data are based on a hospital centred surveillance, which likely underestimates the burden of disease in non-hospitalised children. In addition, children with comorbidities were more likely tested and seen in by the hospital specialists, particularly in the early phase of the pandemic. This is also reflected by the fact that we observe a more severe spectrum of paediatric COVID-19 with a lower rate of asymptomatic children compared to other studies.\textsuperscript{18,19} A further paediatric study from the UK reported much higher rates of comorbidities of 42% in admitted children, but this study did not include data on non-hospitalised cases.\textsuperscript{1} The most frequent comorbidities reported in this study were neurological, asthma and haemato-oncological or immunological which compares to the spectrum reported in our study. Whether underlying conditions are associated with increased severity or a lower threshold for admission is currently unclear.

We found, however, that ICU admission rates are not associated with higher rates of comorbidities. In our setting 13% of hospitalised children required admission to ICU, which is in line with other European studies.\textsuperscript{1,18,20} Similarly, to other studies, children with serious medical conditions (immunodeficiency, haemato-oncological, cardiac or metabolic disease) in our cohort, did not develop severe COVID-19 requiring ICU admission more often than previously healthy children.\textsuperscript{21} A recent systematic review suggests that children with underlying cardiac disease might be at increased risk of severe COVID-19.\textsuperscript{22} However, we did not find this in our study population, where children with underlying cardiac disease (including one patient after heart transplantation) did not experience a severe disease course. Three children with asthma/bronchitis required ICU admission due to respiratory failure. Evidence are sparse on whether asthma is a risk factor for severe COVID-19 in children, a systematic review found only two reports considering asthma as a risk factor for SARS-CoV-2 infection.\textsuperscript{23} However, a large US retrospective paediatric study found that the risk of testing positive was reduced in respiratory disorder, including asthma.\textsuperscript{24} Moreover, asthma children are underrepresented during this pandemic and studies in adults have not identify SARS-CoV-2 as a trigger for asthma exacerbations.\textsuperscript{25} Several hypotheses have been proposed to explain this unexpected finding, including an impaired immune response to SARS-CoV-2. Asthmatic children have lower level of interferon-gamma and consequently reduced angiotensin-converting enzyme 2 (ACE-2) gene expression in airway epithelium, which act as the entry point of SARS-CoV-2 into the human body.\textsuperscript{25} Other studies report reduced ACE-2 expression in patient with allergic asthma or after inhaled corticoid.\textsuperscript{26,27}

Our study clearly shows that the clinical spectrum of COVID-19 is different in hospitalised and non-hospitalised children with fever and rash being more common in those admitted, but cough, rhinorrhoea
and pharyngitis being comparable. Although, fever was the most frequent symptom, especially among young children, the incidence was lower than reported by other multicentric studies.\textsuperscript{1,18,20} This lower prevalence might reflect the higher proportion of adolescents in our cohort. Age is a further important factor influencing the clinical spectrum of disease with fever and respiratory symptoms of lower severity being more frequent in children below 2 years of age. Older children more likely present with non-respiratory symptoms and anosmia/dysgeusia was only rarely recorded in children less than 10 years. A similar spectrum was described in the UK paediatric cohort, however this only included admitted children.\textsuperscript{1}

Our findings confirm that paediatric COVID-19 is mostly a mild illness. Several hypothesis have been proposed to explain the milder disease seen in children, including an age-related difference in immune response, with a stronger innate immune response in children and age-related differences in expression of ACE-2.\textsuperscript{5,28} Of the three deaths reported two were being temporally related to SARS-CoV-2 infection without another disease identified.

Evidence-based treatment options for paediatric COVID-19 are still lacking.\textsuperscript{29} In our study, the majority of non-hospitalised but also hospitalised patients did not receive any specific treatment. However, children admitted to ICU with PIMS-TS clinical picture required inotropic support and benefit from systemic corticosteroid and intravenous immunoglobulins (IVIG) in combination with immunomodulators (including anakinra (interleukin-1 inhibitor) and tocilizumab (interleukin-6 inhibitor)). Similarly, most case series report using IVIG and/or corticosteroid as main therapeutic option for children with PIMS-TS features, given the similitude with Kawasaki disease.\textsuperscript{14,15,30–33} The rational for using anti-cytokine agents (anakinra or tocilizumab) is that these toxic shock-like clinical presentations are caused by exaggerated immune response and excessive cytokine release, called cytokine storm, rather than by viral replication itself.\textsuperscript{34} However, there are insufficient data to recommend for or against the use of specific treatment for PIMS-TS, and management remains centred on effective supportive care.\textsuperscript{29}

The strengths of our study are the inclusion of a large number of children including non-hospitalised children, and the detailed demographic and clinical data. However, our study overestimates the admission rate as we did not include patients tested in private practices and some children were hospitalised for reasons other than SARS-CoV-2 infection. Data from the Federal Office of Public Health show a 0.9% admission rate in children in the same time period (personal communication from Mirjam Mäusezahl, Federal Office of Public Health, 23 March 2021). In addition, in the early weeks of the COVID-19 pandemic SARS-CoV-2 testing was not considered a priority in children and only children with severe symptoms or persistent fever were tested. Testing strategies also differed regionally which may have affected some of the observed regional differences. Analysis of weight and obesity as a potential risk factor for hospitalisation could not be included as weight was not recorded in most non-hospitalised cases. We are also unable to analyse children classified as PIMS-TS in detail as specific data on PIMS-TS cases are only prospectively collected since November 2020.
Conclusions

This study confirms that COVID-19 is mostly a mild disease in children and adolescents with low mortality. Fever, rash, and comorbidities are associated with higher admission rates. The clinical spectrum and severity are influenced by age in paediatric COVID-19. Continuous observation is necessary to further understand paediatric COVID-19, guide therapy and evaluate the necessity for vaccination in children.

Abbreviations

ACE-2, angiotensin-converting enzyme 2; COVID-19, Coronavirus disease-2019; EBV, Epstein-Barr Virus; ICU, intensive care unit; IQR, interquartile range; IVIG, intravenous immunoglobulins; MIS-C, Multisystem inflammatory syndrome in children; PIMS-TS, Paediatric inflammatory multisystem syndrome-temporally associated with SARS-CoV-2; PCR, Polymerase chain reaction; SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2; SPSU, Swiss Paediatric Surveillance Unit;

Declarations

Acknowledgments

We thank the representatives of the pediatric units in Switzerland: M. Albisetti; V. Bernet; C. Betti; F. Cachat; P. Caplazi; M-L. Decker; E. Durrer; S. Fluri; M. Gebauer; M. Gehri; E. Giannoni; S. Grupe; M. Horn; A. L’Huiller; T. Karen; E. Kellner; L. Kottanattu; G. Laube; B. Laubscher; J. Llor; F. Luterbacher; H. Madlon; A. Malzacher; M. Martins; J. McDougall; A. Merglen; S. Minocchieri; V. Muehlethaler; T. Neuhaus; A. Niederer; S. Nikorelou; M. Pleban; Ratnasabapathy; C. Relly, T. Riedel; M. Russo; H. Schmid; K. Staudacher; M. Torres Escobar; J. Wildhaber; A. Wörner; A. Zemmouri

We would also like to acknowledge the administrative support by Daniela Beeli, Mirjam Mäusezahl and Fabien Tschagellar, from the Federal Office of Public Health Switzerland.

Declarations

Authors’ contribution: This study was designed by PZ and NR. Data analysis was done by AU, PZ and NR. AU wrote the first draft; all authors revised the manuscript and approved the final draft.

Funding: The study is supported by the Swiss Federal Office of Public Health and has received grants from the Swiss Society of Paediatrics and the Paediatric Infectious Disease Group of Switzerland.

Competing interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Availability of data and material: Data collected for the study and the study protocol will be made available to others on request.
Code availability: Not applicable

Ethics approval: The study has received ethical approval by the Ethikkommission Nordwest- und Zentralschweiz (EKNZ 2020-01130).

References

1. Swann, O. V. et al. Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: Prospective multicentre observational cohort study. *BMJ* 370, m3249 (2020).
2. Ludvigsson, J. F. Systematic review of COVID-19 in children shows milder cases and a better prognosis than adults. *1088/Acta Paediatr.* 109, 1088–1095 (2020).
3. Zimmermann, P. & Curtis, N. Coronavirus Infections in Children Including COVID-19. *Pediatr. Infect. Dis. J.* 39, 355–368 (2020).
4. Dong, Y. et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics* 145, e20200702 (2020).
5. Zimmermann, P. & Curtis, N. Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections. 1–11 (2020). doi:10.1136/archdischild-2020-320338
6. Oberweis, M.-L. et al. Pediatric Life-Threatening Coronavirus Disease 2019 With Myocarditis. *Pediatr. Infect. Dis. J. Publish Ah*, 1088–1095 (2020).
7. Riphagen, S., Gomez, X., Gonzalez-martinez, C., Wilkinson, N. & Theocharis, P. Correspondence Hyperinflammatory shock in children during. *Lancet* 6736, 2019–2020 (2020).
8. Zimmermann, P., Goetzinger, F. & Ritz, N. Additional Concerns Regarding Children With Coronavirus Disease 2019. *JAMA Pediatr.* 174, 1216 (2020).
9. Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* 395, 1771–1778 (2020).
10. Viner, R. M. & Whittaker, E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. *Lancet* 395, 1741–1743 (2020).
11. Jones, V. G. et al. COVID-19 and Kawasaki Disease: Novel Virus and Novel Case. (2020). doi:10.1542/hpeds.2020-0123
12. Toubiana, J. et al. Kawasaki-like multisystem inflammatory syndrome in children during the covid-19 pandemic in Paris, France: prospective observational study. doi:10.1136/bmj.m2094
13. Levin, M. Ed i t o r i a l Childhood Multisystem Inflammatory Syndrome-A New Challenge in the Pandemic. (2020). doi:10.1056/NEJMoa2021756
14. Moraleda, C. et al. Multi-inflammatory Syndrome in Children Related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Spain. *Clin. Infect. Dis.* (2020). doi:10.1093/cid/ciaa1042
15. Cheung, E. W. *et al.* Multisystem Inflammatory Syndrome Related to COVID-19 in Previously Healthy Children and Adolescents in New York City. *JAMA* 324, 294 (2020).
16. Wright, A. REDCap: A Tool for the Electronic Capture of Research Data. *J. Electron. Resour. Med. Libr* 13, 197–201 (2016).
17. Stokes, E. K. *et al.* Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. *MMWR. Morb. Mortal. Wkly. Rep.* 69, 759–765 (2020).
18. Parri, N. *et al.* Characteristic of COVID-19 infection in pediatric patients: early findings from two Italian Pediatric Research Networks. *Eur. J. Pediatr.* 179, 1315–1323 (2020).
19. Maltezou, H. C. *et al.* Children and Adolescents With SARS-CoV-2 Infection: Epidemiology, Clinical Course and Viral Loads. *Pediatr. Infect. Dis. J.* 39, e388–e392 (2020).
20. Götzinger, F. *et al.* COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *Lancet Child Adolesc. Heal.* 4, 653–661 (2020).
21. Issitt, R. *et al.* Coronavirus (COVID-19) infection in children at a specialist centre: outcome and implications of underlying high-risk comorbidities in a paediatric population. (2020). doi:10.1101/2020.05.20.20107904
22. Williams, N. *et al.* COVID-19 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children and adolescents: a systematic review of critically unwell children and the association with underlying comorbidities. *Eur. J. Pediatr.* 2, (2020).
23. Castro-Rodriguez, J. A. & Fomo, E. Asthma and COVID-19 in children: A systematic review and call for data. *Pediatr. Pulmonol.* 55, 2412–2418 (2020).
24. Bailey, L. C. *et al.* Assessment of 135794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 across the United States. *JAMA Pediatr.* 1–9 (2020). doi:10.1001/jamapediatrics.2020.5052
25. Wang, J., Pawankar, R., Tsai, H., Wu, L. S. & Kuo, W. COVID-19 and asthma, the good or the bad? *Allergy* all.14480 (2020). doi:10.1111/all.14480
26. Jackson, D. J. *et al.* Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. *J. Allergy Clin. Immunol.* 146, 203-206.e3 (2020).
27. Peters, M. C. *et al.* COVID-19-related genes in sputum cells in asthma: Relationship to demographic features and corticosteroids. *Am. J. Respir. Crit. Care Med.* 202, 83–90 (2020).
28. Bunyavanich, S., Do, A. & Vicencio, A. Nasal Gene Expression of Angiotensin-Converting Enzyme 2 in Children and Adults. *JAMA* 323, 2427 (2020).
29. NIH. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. *Nih* 2019, 130 (2020).
30. Tanner, T. & Wahezi, D. M. Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19. *Paediatr. Respir. Rev.* 35, 81–87 (2020).
31. Whittaker, E. *et al.* Clinical Characteristics of 58 Children With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 Group Information: The PIMS-TS Study Group
32. Viner, R. M. et al. Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults A Systematic Review and Meta-analysis Editorial Supplemental content. (2020). doi:10.1001/jamapediatrics.2020.4573

33. Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. www.thelancet.com395, (2020).

34. Sanders, J. M., Monogue, M. L., Jodlowski, T. Z. & Cutrell, J. B. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA - J. Am. Med. Assoc.323, 1824–1836 (2020).

Table 1 Baseline characteristics and clinical information of children with SARS-CoV-2 infections
|                  | Overall n=678 | Non-hospitalised n=552 | All hospitalised* n=126 | ICU n=16 |
|------------------|--------------|------------------------|-------------------------|----------|
| **Age in years** |              |                        |                         |          |
| <2               | 117 (17.3)   | 52 (9.4)               | 65 (51.6)               | 4 (25.0) |
| 2 to <5          | 49 (7.2)     | 42 (7.6)               | 7 (5.6)                 | 0 (0.0)  |
| 5 to <10         | 99 (14.6)    | 85 (15.4)              | 14 (11.1)               | 2 (12.5) |
| ≥10              | 413 (60.9)   | 373 (67.6)             | 40 (31.7)               | 10 (62.5)|
| **Age <1 month** | 17 (2.5)     | 5 (0.9)                | 12 (9.5)                | 1 (6.2)  |
| **Female**       | 316 (46.6)   | 262 (47.5)             | 54 (42.9)               | 5 (31.3) |
| **Comorbidities**| 106 (15.6)   | 72 (13.0)              | 34 (27.0)               | 5 (31.3) |
| **Symptoms**     |              |                        |                         |          |
| Fever            | 305 (45.3)   | 209 (38.1)             | 96 (76.2)               | 11 (68.8)|
| Cough            | 277 (41.2)   | 229 (41.8)             | 48 (38.4)               | 4 (26.7) |
| Rhinorrhoea      | 191 (28.4)   | 142 (25.9)             | 49 (39.2)               | 4 (26.7) |
| Pharyngitis      | 187 (27.8)   | 164 (29.9)             | 23 (18.4)               | 3 (20.0) |
| Anosmia/dysgeusia| 76 (11.3)    | 73 (13.3)              | 3 (2.4)                 | 1 (6.7)  |
| Abdominal pain   | 76 (11.3)    | 60 (10.9)              | 16 (12.8)               | 5 (33.3) |
| Diarrhoea        | 68 (10.1)    | 46 (8.4)               | 22 (17.6)               | 5 (33.3) |
| Vomiting         | 59 (8.8)     | 37 (6.8)               | 22 (17.6)               | 5 (33.3) |
| Respiratory distress | 49 (7.3) | 18 (3.3) | 31 (24.6) | 10 (62.5) |
| Rash             | 22 (3.3)     | 6 (1.1)                | 16 (12.8)               | 5 (33.3) |
| Oxygen saturation <92% | 18 (2.7) | 1 (0.2) | 17 (13.5) | 6 (37.5) |
| Asymptomatic     | 39 (5.8)     | 35 (6.3)               | 4 (3.2)                 | 0 (0.0)  |

* Numbers of hospitalised children include those admitted to ICU

ICU - intensive care unit

**Table 2 Reported comorbidities. Note that some patients were reported with more than one comorbidity**
| Any pre-existing comorbidities | Overall n (%) | Non-hospitalised n (%) | All Hospitalised* n (%) | ICU n (%) |
|--------------------------------|---------------|-------------------------|-------------------------|-----------|
| **Any pre-existing comorbidities** | 106 (100) | 72 (13) | 34 (27.0) | 5 (31.3) |
| **Respiratory disease** | 45 (42.5) | 31 (43.1) | 14 (41.2) | 4 (80.0) |
| Asthma/bronchitis | 38 | 30 | 8 | 3 |
| Obstructive sleep apnoea/adenoid hypertrophy | 2 | 0 | 2 | 0 |
| Cystic fibrosis/primary ciliary dyskinesia | 2 | 0 | 2 | 0 |
| Apnoea of prematurity | 2 | 0 | 2 | 1 |
| Bronchopulmonary dysplasia | 1 | 1 | 0 | 0 |
| **Endocrinological disease** | 15 (14.2) | 12 (16.7) | 4 (11.8) | 0 |
| Obesity | 10 | 8 | 2 | 0 |
| Diabetes mellitus type 1 | 5 | 3 | 2 | 0 |
| Hashimoto thyroiditis | 1 | 1 | 0 | 0 |
| **Haemato-oncological disease** | 12 (11.3) | 5 (6.9) | 7 (20.6) | 1 (20.0) |
| Leukaemia | 5 | 2 | 3 | 0 |
| Thalassemia/sickle-cell disease | 2 | 1 | 1 | 0 |
| Neutropenia | 2 | 0 | 2 | 1 |
| Medulloblastoma | 1 | 1 | 0 | 0 |
| Severe anaemia | 1 | 0 | 1 | 0 |
| Glucose-6-dehydrogenase deficiency | 1 | 1 | 0 | 0 |
| **Cardiovascular disease** | 10 (9.4) | 5 (6.9) | 5 (14.7) | 0 |
| Congenital heart defect | 6 | 2 | 4 | 0 |
| Post heart transplant | 1 | 0 | 1 | 0 |
| Myocarditis | 1 | 1 | 0 | 0 |
| Hypertrophic cardiomyopathy | 1 | 1 | 0 | 0 |
| sclerosis | count 0 | count 1 | count 2 |
|----------|---------|---------|---------|
| Familial long QT syndrome | 1 | 1 | 0 |
| **Neurologic disease** | 8 (7.5) | 4 (5.6) | 4 (11.8) | 1 (20.0) |
| Psychiatric | 2 | 0 | 2 |
| Epilepsy | 2 | 2 | 0 |
| Microcephaly | 1 | 0 | 1 |
| Neurofibromatosis | 1 | 1 | 0 |
| Multiple strokes | 1 | 0 | 1 |
| Autistic spectrum disorder | 1 | 1 | 0 |
| **Surgical comorbidities** | 6 (5.7) | 5 (6.9) | 1 (2.9) | 0 |
| **Immunodeficiency** | 5 (4.7) | 2 (2.8) | 3 (8.8) | 0 |
| Commune variable immune deficiency | 1 | 0 | 1 |
| Microdeletion 22q11 | 1 | 0 | 1 |
| Autoimmune lymphoproliferative syndrome | 1 | 1 | 0 |
| Complement activation deficiency | 1 | 1 | 0 |
| Status post renal transplant | 1 | 0 | 1 |
| **Nephrological disease** | 5 (4.7) | 1 (1.4) | 4 (11.8) | 0 |
| Urolithiasis | 1 | 0 | 1 |
| Hydronephrosis | 1 | 1 | 0 |
| Kidney failure | 2 | 0 | 2 |
| Autosomal recessive polycystic kidney disease | 1 | 0 | 1 |
| **Genetic disease** | 4 (3.8) | 2 (2.8) | 2 (5.9) | 0 |
| Von Hippel Lindau | 1 | 1 | 0 |
| Down disease | 2 | 1 | 1 |
| Mowat Wilson syndrome | 1 | 0 | 1 |
| **Auto-immune disease** | 4 (3.8) | 3 (4.2) | 1 (2.9) | 0 |
| Juvenile idiopathic arthritis | 3 | 3 | 0 |
| Granulomatosis with polyangiitis | 1 | 0 | 1 |
| **Auto-inflammatory disease** | 3 (2.8) | 3 (4.2) | 0 | 0 |
| Condition                          | Univariable regression | Multivariable regression |
|-----------------------------------|------------------------|--------------------------|
|                                  | OR         | 95% CI      | p-value  | OR         | 95% CI      | p-value  |
| Age < 2 years (Reference)         | 1.23       | 0.85 to 1.78| 0.27     | 1.52       | 0.72 to 3.24| 0.27     |
| Age 2 to <5 years                 | 0.14       | 0.05 to 0.31| <0.01    | 0.10       | 0.04 to 0.24| <0.01    |
| Age 5 to <10 years                | 0.13       | 0.07 to 0.26| <0.01    | 0.11       | 0.05 to 0.22| <0.01    |
| Age >10 years                     | 0.09       | 0.05 to 0.14| <0.01    | 0.08       | 0.05 to 0.13| <0.01    |
| Gender (male)                     | 0.81       | 0.55 to 1.20| 0.31     | 0.78       | 0.50 to 1.21| 0.27     |
| Comorbidities (Any)               | 2.49       | 1.55 to 3.95| <0.01    | 3.23       | 1.89 to 5.50| <0.01    |
| Cardiac comorbidities             | 4.56       | 1.25 to 16.63| 0.02    | -          | -            | -        |
| Respiratory comorbidities         | 2.12       | 1.06 to 4.04| 0.03    | -          | -            | -        |
| Immunodeficiency                  | 6.76       | 1.11 to 51.75| 0.04    | -          | -            | -        |
| Haemato-oncological comorbidities | 6.49       | 2.04 to 22.26| <0.01    | -          | -            | -        |

* Numbers of hospitalised children include those admitted to ICU

Table 3 Univariable and multivariable regression analysis for risk of hospitalisation. The number of specific comorbidities were too low to be included in the multivariable analysis.
**Figure 1**

Number of children with SARS-CoV-2 infections over time.
Other symptoms included conjunctivitis, otalgia, cheilitis, hand oedema, thoracic pain, arthralgia, acrocyanosis, fainting, seizure, aiguria, orchitis and macro-haematuria.

**Figure 2**

Symptoms distribution in non-hospitalised and hospitalised children with SARS-CoV-2 infections according to age group.
Figure 3
Heatmap using k-means with symptom cluster (the colour code stands for the number of children with corresponding symptoms)

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalmaterialSARSCoV2infectionquestionnaire.pdf